Pulmonx is a pioneering brand that specializes in improving breathing and enhancing the quality of life for patients with severe emphysema, a form of COPD. Their breakthrough product, the Zephyr Endobronchial Valve Therapy, offers a minimally invasive treatment option for emphysema, providing durable clinical benefits without the need for surgery and its associated risks. With a focus on patient selection and precise identification, Pulmonx provides a comprehensive solution for healthcare professionals.

The Zephyr Valve, the first FDA-approved endobronchial valve, ensures targeted treatment for both heterogenous and homogeneous emphysema. Patients who undergo Zephyr Valve treatment experience improved lung function, increased exercise capacity, reduced breathlessness, and enhanced quality of life. The brand is dedicated to revolutionizing patient care by offering clinically proven, safe, and effective treatment options.

By utilizing Pulmonx's innovative technology, individuals with severe emphysema can enjoy a more active and fulfilling life